JR

Jean-François Rivassou

Partner chez Kurma Partners

Paris, Île-de-France

Invests in

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Corporate Development
Venture Capital
Internet
Biotechnology
Medtech
M&A experience
Life Sciences
classifieds
Digital Media
B2B services
Start-ups
Investments
New Business Development
International Development
capital risque
capital developpement
biotechnologie
Web
Strategy
Private Equity

Education

  • Ingénieur Civil/ Civil Engineer

    (1995 - 1998)

  • Mathématiques supérieures et spéciales

    (1993 - 1995)

  • Baccalauréat scientifique

    Lycée G.Cabanis - Brive-la-Gaillarde

    (1990 - 1993)

Work Experience

  • Partner

    2021

    Founded in July 2009 and based in Paris and Munich, Kurma Partners is a key European player in the financing of innovation in Healthcare and Biotechnology, from pre-seed to growth capital, with circa 700 M€ under management. The company has forged links with a network of prestigious research institutes and hospitals and addresses the therapeutic as well as the diagnostics and digital health areas. Since September 2021 Kurma Partners is majority owned by Eurazeo, a leading global investment group.

  • Board Member

    2022

    GERMITEC is committed to providing healthcare professionals and patients with safe, simple and automated UV-C solutions for ultrasound probe disinfection, replacing chemistry with photons to radically simplify the lives of healthcare professionals in terms of safety, time and liability. With 15 years of experience in the design and development of sustainable hospital hygiene solutions, GERMITEC is a market leader with a proven track record of product development and sales growth and strong prospects for expansion. www.germitec.com

2018 - 2020

  • Board Observer

    2018 - 2020

    M33, la structure de tête du groupe Theodo, rassemble aujourd’hui 8 entreprises spécialisées dans la création de solutions digitales au service des entreprises : Theodo, Theodo UK et Nimble Ways (Maroc) sont spécialisées dans le web, BAM dans le mobile, Sicara dans la data science et Sipios dans la fintech, Padok dans le Cloud/DevOps, Hokla dans les dispositifs médicaux numériques. www.m33.tech www.theodo.fr www.theodo.co.uk www.nimbleways.com www.bam.tech www.sicara.com www.sipios.com www.padok.fr www.hokla.com

2015 - 2020

  • Board member

    2015 - 2020

    The global high impact advertising market place. Innovative and highly impactful formats available on multi-device. Paris, London, Singapore, Madrid, Milan, Düsseldorf. #Brandtech http://www.sublime.xyz/

2013 - 2020

  • Investment Director

    2013 - 2020

    Investment Director for the ISAI Expansion fund (150m€ Private Equity Fund) at ISAI Gestion (500m€ AUM). Growth equity, secondary deals or LBO/OBO in digital companies. Portfolio companies followed : - Sublime : www.sublime.xyz - Eulerian : www.eulerian.com - M33/Theodo : www.m33.tech - Pandat Finance : www.pandat.fr

2006 - 2012

  • Corporate Business Development Manager (M&A)

    2006 - 2012

    Member of the Management Committee 7 acquisitions completed for a total amount exceeding 30 M€ in France, Germany and UK Figaro Classifieds (Le Figaro Group, formerly Adenclassifieds, listed on Euronext Paris), a French leading online company. Online job and property classifieds and B2B solutions Main websites/brands : cadremploi.fr, keljob.com, explorimmo.com - Sourcing, analysis and selection of acquisition opportunities - Presentation to the Board of Directors, negotiation of contract terms - Supervision of the integration of newly acquired companies - Strategic partnerships with media groups (Web and print) : traffic acquisition, reseller agreements, …

Banexi Ventures

2000 - 2005

  • Investment Manager Life Sciences (Biotech/Medtech)

    2000 - 2005

    VC branch of BNP Paribas More than 300 M€ under management dedicated to early stage investments (IT, Internet and Biotech/Medtech) : - Sourcing, investment in start ups - Follow up (reporting, board meeting, shareholder meeting) - Exits : IPO, trade sale

Genset Singapore Biotechnology Pte Ltd

1999 - 2000

  • Assistant to the general manager

    1999 - 2000

    Nasdaq listed company Genomics and synthetic DNA manufacturing - Sales, logistics, invoicing - Development of the newly established Asian subsidiary - Market and technological intelligence